Russell Investments Group Ltd. Sells 4,771 Shares of SI-BONE, Inc. (NASDAQ:SIBN)

Russell Investments Group Ltd. decreased its position in shares of SI-BONE, Inc. (NASDAQ:SIBN) by 18.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 21,461 shares of the company’s stock after selling 4,771 shares during the quarter. Russell Investments Group Ltd. owned about 0.06% of SI-BONE worth $422,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. JPMorgan Chase & Co. lifted its position in SI-BONE by 37.9% in the 1st quarter. JPMorgan Chase & Co. now owns 167,745 shares of the company’s stock valued at $3,791,000 after acquiring an additional 46,086 shares in the last quarter. HighTower Advisors LLC bought a new stake in SI-BONE during the first quarter worth $220,000. MetLife Investment Management LLC raised its position in SI-BONE by 54.2% in the 1st quarter. MetLife Investment Management LLC now owns 18,825 shares of the company’s stock valued at $425,000 after buying an additional 6,615 shares during the last quarter. Rhumbline Advisers lifted its stake in SI-BONE by 8.3% during the 1st quarter. Rhumbline Advisers now owns 32,233 shares of the company’s stock valued at $728,000 after acquiring an additional 2,476 shares in the last quarter. Finally, BlackRock Inc. grew its stake in shares of SI-BONE by 0.4% in the 1st quarter. BlackRock Inc. now owns 2,709,443 shares of the company’s stock worth $61,233,000 after acquiring an additional 9,645 shares in the last quarter.

Insiders Place Their Bets

In related news, Director John Gordon Freund sold 30,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 9th. The shares were sold at an average price of $20.54, for a total transaction of $616,200.00. Following the sale, the director now owns 103,899 shares of the company’s stock, valued at approximately $2,134,085.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other SI-BONE news, CEO Laura Francis sold 9,012 shares of the company’s stock in a transaction that occurred on Wednesday, August 16th. The stock was sold at an average price of $20.96, for a total transaction of $188,891.52. Following the completion of the transaction, the chief executive officer now owns 437,039 shares of the company’s stock, valued at approximately $9,160,337.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director John Gordon Freund sold 30,000 shares of the firm’s stock in a transaction on Wednesday, August 9th. The stock was sold at an average price of $20.54, for a total value of $616,200.00. Following the completion of the sale, the director now directly owns 103,899 shares of the company’s stock, valued at approximately $2,134,085.46. The disclosure for this sale can be found here. Insiders sold a total of 85,038 shares of company stock worth $1,853,427 in the last quarter. 5.40% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on SIBN. Bank of America upped their price objective on shares of SI-BONE from $28.00 to $33.00 in a research report on Wednesday, June 14th. Truist Financial dropped their price target on SI-BONE from $33.00 to $31.00 and set a “buy” rating on the stock in a report on Tuesday, August 8th. Cantor Fitzgerald restated an “overweight” rating and issued a $30.00 price objective on shares of SI-BONE in a research note on Tuesday, August 22nd. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $32.00 price objective on shares of SI-BONE in a research report on Tuesday, August 8th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $28.00.

SI-BONE Price Performance

Shares of NASDAQ:SIBN opened at $22.61 on Monday. The company has a 50-day moving average price of $24.27 and a two-hundred day moving average price of $22.98. The firm has a market capitalization of $874.69 million, a PE ratio of -16.75 and a beta of 0.95. SI-BONE, Inc. has a twelve month low of $11.14 and a twelve month high of $29.51. The company has a quick ratio of 10.55, a current ratio of 11.68 and a debt-to-equity ratio of 0.20.

SI-BONE (NASDAQ:SIBN) last posted its earnings results on Monday, August 7th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.11. The firm had revenue of $33.31 million for the quarter, compared to the consensus estimate of $32.24 million. SI-BONE had a negative return on equity of 40.35% and a negative net margin of 38.32%. Equities analysts forecast that SI-BONE, Inc. will post -1.25 EPS for the current year.

About SI-BONE

SI-BONE, Inc, a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma.